For Providers

PROphet^® NSCLC guides first-line PD-1/PD-L1 inhibitor treatment decisions for metastatic NSCLC patients by accurately predicting likelihood of clinical benefit and overall survival when administered as a single agent vs. in combination with chemotherapy.

The PROphet^® model was developed  based on clinical, demographic, and proteomic data of over 600 patients within the framework of an ongoing clinical study conducted by OncoHost (PROPHETIC; NCT04056247). To date, the trial has over 1,700 patients recruited across 40 sites worldwide, making it one of the largest prospective cohorts in the precision oncology field.

Plasma was isolated from the blood and profiled via the SomaScan^® Discovery Assay v4.1[2-3], and the resulting proteomic profiles were analyzed in conjunction with patient clinical data. The clinical benefit prediction algorithm was developed to identify patients who are more likely to benefit from PD-1/PD-L1 inhibitor treatment. Patient clinical benefit probability is predicted and linearly transformed to a PROphet^® Score between 0 to 10.

The PROphetNSCLC^™ test is supported by a blinded validation demonstrating that it accurately predicts a patient’s clinical benefit and associated overall survival differences with single-agent versus combination treatment plans.

View all our clinical evidence here.

Proteomics and next-generation sequencing (NGS) are complementary approaches in understanding cancer dynamics. PROphetNSCLC^™ focuses on proteomic pattern analysis, revealing biomarkers that indicate biological processes within the tumor and the body, influencing treatment success.

On the other hand, NGS examines the genomic and genetic makeup of the tumor, identifying crucial genetic alterations which guide your overall treatment planning. Integrating proteomic analysis with NGS can provide you with valuable insights into your patient’s tumor growth, characteristics, and predicted response to treatment.

While immunotherapy has shown remarkable success in some cases, not all patients respond equally, and resistance to treatment can be a significant challenge.

Proteomics provides insights into the complex interactions between the immune system and cancer cells at a molecular level. By analyzing protein expression patterns, we can identify biomarkers that predict patient response to immunotherapy.

Proteomics also provides insights into the tumor microenvironment, revealing crucial interactions between cancer and immune cells. The tumor microenvironment plays a vital role in influencing the effectiveness of immunotherapy, and proteomics can provide information about the types and quantities of immune cells present, as well as the signaling molecules and proteins secreted by both cancer and immune cells. Understanding these interactions can help reveal mechanisms of resistance and suggest ways to overcome them.

By leveraging proteomic insights, we can tailor treatments based on individual patient profiles, leading to more effective and personalized cancer care and, ultimately, improving patient outcomes.

OncoHost will send a mobile phlebotomist to draw one pre-treatment blood test from the comfort of the patient’s home or at the patient’s preferred location. OncoHost will be in touch with the patient directly to coordinate the appointment.

Yes. Contact our Client Services team to coordinate this option for your clinic: contact@oncohost.com or 1-855-950-2112.

0.2 microliters.

The patient must be newly diagnosed with metastatic non-small cell lung cancer (NSCLC) and immunotherapy naïve.

No, PD-L1 testing should be completed using your regular provider. PROphet^® NSCLC is ordered at the same time as NGS and PD-L1 so that all results are available to you at the time of treatment planning.

Combining the PROphet^® NSCLC test results with the PD-L1 score provides additional information on the patient’s expected response, which may support the choice of first-line therapy and affect the patient over time. 

PROphet^® NSCLC predicts differential overall survival (OS) and progression-free survival (PFS) outcomes when combined with PD-L1 expression level.

This will provide you with valuable insights into your patient’s first-line treatment plan, offering treatment considerations for therapies they are likely to respond to based on their personalized proteomic analysis.

This means that the patient has a high likelihood of achieving clinical benefit on an approved PD-1/PD-L1 inhibitor immunotherapy regimen.

Online ordering: Order online by logging in or signing up for a physician portal account here.
Fax ordering: Download our test requisition form (TRF) here and fax it completed to 1-919-415-1308.

• OncoHost will bill your patient’s insurance company once the report has been completed.
• The patient may receive an explanation of benefits (EOB) notice from their insurance company. This is not a bill.
• The patient is only responsible for their co-insurance based on the amount allowed by their plan; they will not be balance billed.
• If the appeal for the claim is denied, they are not balance billed.
• OncoHost accepts a final allowable amount from the payor after our appeal process is completed.
• If the patient owes any out-of-pocket costs, they will receive a bill directly from OncoHost, along with the contact details of our Financial Assistance Program.
• Financial assistance is available for qualifying patients who have out-of-pocket costs associated with OncoHost’s PROphetNSCLC^™ test.*
• Financial assistance is based on need, and can be applied for at any time before, during, or after testing.
• For any additional information or questions about our billing process, insurance, or Medicare coverage, please reach out to our Client Services team at contact@oncohost.com or 1-855-950-2112.

In effect until December 31, 2024

*OncoHost’s Financial Assistance Program is only available to patients whose tests were ordered within the United States and U.S. territories.

Total turnaround time is 7-14 business days.

Yes. Please find our laboratory’s licensing certificates and permits here.

PROphetNSCLC^™ test reports can be accessed as soon as results are ready via our digital physician portal: Log in or sign up for an account. If you faxed us your TRF, your results will be faxed back to you.

The PROphet^® NSCLC test is currently available to order in every US state except for New York (pending).

In the pipeline:

• PROphet^® Melanoma
• PROphet^® SCLC (small cell lung cancer)
• PROphet^® HNC (head and neck cancers)
• PROphet^® RCC (renal cell carcinoma)
• PROphet^® IrAE (immune-related adverse events) - Learn more here.
• IcAR (Immune-checkpoint Artificial Reporter) test - Learn more here.

To learn more about signing your practice up for OncoHost’s physician portal or ordering a test, please contact your Regional Sales Director, or reach out to our Client Services team at contact@oncohost.com or 1-855-950-2112.

For issues related to OncoHost physician portal accounts, please email contact@oncohost.com.

For any portal password-related issues, please contact our Client Services team contact@oncohost.com or call 1-855-950-2112 during business hours (Mon-Fri, 8:00am-5:00pm).